Industry | 2022.04.21
Catalent to Invest $350 Million in Integrated Biologics Drug Substance and Drug Product Manufacturing at Bloomington, Indiana, Facility
Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced a multi-year $350 million investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities. The project will serve the industry’s robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex automated packaging.
(PRWeb April 21, 2022)
Read the full story at https://www.prweb.com/releases/catalent_to_invest_350_million_in_integrated_biologics_drug_substance_and_drug_product_manufacturing_at_bloomington_indiana_facility/prweb18632268.htm
For more information, please visit
https://www.prweb.com/releases/catalent_[...]ana_facility/prweb18632268.htm
